Broadwood Partners, L.P. has demonstrated a consistent and aggressive buying strategy, with no selling activity reported across its 75 transactions involving two companies. The firm has deployed over $111.9 million exclusively into purchases, with a clear concentration on STAAR Surgical Company (STAA) and a smaller position in an unspecified company under the ticker IMDX. The most substantial STAA acquisitions occurred in November 2025, with three consecutive days of high-volume buying totaling $41.06 million—including a single-day purchase worth $22.22 million on November 21. Activity intensified again in early 2026, with Broadwood adding $12.26 million in STAA shares between March 11-13, including a $5.88 million purchase on March 13. The firm also allocated $3 million to IMDX on February 10, 2026, marking its only non-STAA investment in the dataset. Smaller but recurring STAA purchases throughout January 2026—ranging from $71,082 to $3.93 million—suggest ongoing accumulation. The complete absence of sell transactions and the repeated pattern of multi-million-dollar buy orders indicate Broadwood maintains a strong directional bias toward these holdings, with STAA representing the overwhelming focus of its investment activity.
AI-assisted summary